In this third article of our series on QC, we are sharing our thoughts on the best way for biotech companies to address analytical development for characterisation of their biotherapeutic candidate at preclinical and clinical stages.
What methods to use for glycan characterisation of your antibody and protein products during process development?
In this second article of our series on QC development for biotherapeutics, our partner PROTEODYNAMICS, an expert company in glycan analysis and protein characterisation, gives a review of the relevant methods to characterise the glycosylation of your biotherapeutic candidates.
We are starting a series of articles addressing the question of QC development for biotherapeutic projects and have asked IDBiotech, which specialises in ELISA development, to explain why the quantification of HCPs is a key point to consider in CMC strategy.
How to choose a method for protein size analysis (and also learn why the sky is blue and the sunset red)
Published on 2015-01-30 Analytics
What you will read about: How to choose the right method for protein size analysis and aggregation state characterisation?